MEIP 1.57 - adding to this beatendownbio trading at cash for 2 reasons.
1. Very similar to CNAT (whaddarun congrats to those that held on) in that a large biotech, Helsinn Healthcare SA, infused them with a ton of cash and has agreed to pick up all Phase3 expenses.
2. Q3 filed on 5/4/17 notes 3 upcoming catalysts in June.
They also filed an S3 on 5/4/17 which might be good or bad imo. Love the risk-side here because it trades at cash with most future expenses covered under the Helsinn agreement.